Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,130,636
  • Shares Outstanding, K 656,687
  • Annual Sales, $ 1,549 M
  • Annual Income, $ 728,930 K
  • 60-Month Beta 0.89
  • Price/Sales 18.72
  • Price/Cash Flow 37.65
  • Price/Book 8.81
Trade GMAB with:

Options Overview

Details
  • Implied Volatility 45.21%
  • Historical Volatility 14.74%
  • IV Percentile 38%
  • IV Rank 24.80%
  • IV High 81.23% on 03/08/21
  • IV Low 33.33% on 07/21/21
  • Put/Call Vol Ratio 0.75
  • Today's Volume 7
  • Volume Avg (30-Day) 106
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 2,990
  • Open Int (30-Day) 3,048

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.08
  • Number of Estimates 5
  • High Estimate 0.11
  • Low Estimate 0.06
  • Prior Year 0.76
  • Growth Rate Est. (year over year) -89.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.62 +10.47%
on 07/01/21
45.21 -0.75%
on 07/23/21
+3.06 (+7.32%)
since 06/23/21
3-Month
35.45 +26.57%
on 05/04/21
45.21 -0.75%
on 07/23/21
+8.06 (+21.90%)
since 04/23/21
52-Week
30.10 +49.07%
on 03/04/21
45.21 -0.75%
on 07/23/21
+9.11 (+25.48%)
since 07/23/20

Most Recent Stories

More News
ALXN or GMAB: Which Is the Better Value Stock Right Now?

ALXN vs. GMAB: Which Stock Is the Better Value Option?

ALXN : 182.50 (+1.70%)
GMAB : 44.91 (+1.24%)
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Genmab A/S (Nasdaq: GMAB) and Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced today that the companies have entered into an oncology research and development collaboration. Together, the companies...

GNMSF : 452.6700 (+0.83%)
GMAB : 44.91 (+1.24%)
BOLT : 12.40 (-3.43%)
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

RHHBY : 46.9950 (+1.24%)
GSK : 39.52 (+0.74%)
SGEN : 145.61 (+1.59%)
GMAB : 44.91 (+1.24%)
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review

The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.

SGEN : 145.61 (+1.59%)
RGEN : 210.00 (+1.94%)
NBRV : 1.1200 (-1.75%)
GMAB : 44.91 (+1.24%)
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking...

GNMSF : 452.6700 (+0.83%)
GMAB : 44.91 (+1.24%)
SGEN : 145.61 (+1.59%)
Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

--- BLA Submission Supported by Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 -

SGEN : 145.61 (+1.59%)
GMAB : 44.91 (+1.24%)
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance

The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

RHHBY : 46.9950 (+1.24%)
MRK : 77.48 (+1.24%)
SGEN : 145.61 (+1.59%)
GMAB : 44.91 (+1.24%)
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug

Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.

ACOR : 4.68 (+22.83%)
SGEN : 145.61 (+1.59%)
EPZM : 6.96 (-1.69%)
GMAB : 44.91 (+1.24%)
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval...

SGEN : 145.61 (+1.59%)
GMAB : 44.91 (+1.24%)
3 Top Biotech Stocks to Buy in February

Biotech stocks attracted maximum attention in 2020 due to the COVID-19 pandemic and a worldwide scramble to develop vaccines. Favorable news surrounding vaccines has boosted confidence generally that biotech...

GILD : 69.01 (+0.52%)
SGEN : 145.61 (+1.59%)
GMAB : 44.91 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 45.00
2nd Resistance Point 44.85
1st Resistance Point 44.61
Last Price 44.91
1st Support Level 44.22
2nd Support Level 44.07
3rd Support Level 43.83

See More

52-Week High 45.21
Last Price 44.91
Fibonacci 61.8% 39.44
Fibonacci 50% 37.65
Fibonacci 38.2% 35.87
52-Week Low 30.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar